Skip to main content

Advertisement

Springer Nature Link
Log in

Thrombosis and bleeding in cancer patients

  • Review
  • Published:
Oncology Reviews

Abstract

It is well recognized that thrombosis and bleeding are two major complications seen in cancer patients. Recent advances in both basic and clinical observations have enhanced our understanding of the pathogenesis of both phenomena. In this article, the significance of thrombotic complications is reviewed first. This is followed by a detailed discussion of the present day concept of thrombogenesis in cancer based on Virchow’s original triad of aberrant blood flow, loss of vascular integrity and altered blood components. While most cancer patients experience bleeding at some time during the course of their illness, there are special situations that increase bleeding diathesis. These include thrombocytopenia, endothelial injury, acquired hemophilia and adverse effects of drugs.

Recognition of these factors will assit in the adoption of appropriate preventive and therapeutic measures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Virchow R. Phlogose und Thrombose in gefabsystem. In: Virchow R (ed) Gesammelte Abdhandlunhen zur Wissenschaftlicgen Medicin. Von Meidinger Sohn, Frankfurt 1856:458

    Google Scholar 

  2. Trousseau A (1865) Phlegmasia Alba Dolens. Clinique Médicale de l’Hôtel Dieu de Paris. Baillière, Paris 659–712

    Google Scholar 

  3. Costantini V, De Monte P, Cazzato AO et al (1998) Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation. Blood Coagul Fibrinolysis 9:79–84

    PubMed  CAS  Google Scholar 

  4. Goldenberg N, Kahn SR, Solymoss S (2003) Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 21:4194–4199

    PubMed  CAS  Google Scholar 

  5. Johnson MJ, Walker ID, Sproule MW et al (1999) Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 21:51–54

    PubMed  CAS  Google Scholar 

  6. Ozyilkan O, Baltali E, Ozdemir O et al (1998) Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer. Tumori 84:364–367

    PubMed  CAS  Google Scholar 

  7. Rickles FR, Levine MN (2001) Epidemiology of thrombosis in cancer. Acta Haematol 106:6–12

    PubMed  CAS  Google Scholar 

  8. White RH, Chew HK, Zhou H et al (2005) Incidence of venous thromboembolism in the year before the diagnosis of cancer in adults. Arch Intern Med 165:1782–1787

    PubMed  Google Scholar 

  9. Murchison JT, Wylie L, Stockton DL (2004) Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 91:92–95

    PubMed  CAS  Google Scholar 

  10. Khorana AA, Francis CW, Culakova E et al (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484–490

    PubMed  Google Scholar 

  11. Otten HM, Mathijssen J, Ten Cate H et al (2004) Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 164:190–194

    PubMed  Google Scholar 

  12. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722

    PubMed  CAS  Google Scholar 

  13. Mohren M, Markmann I, Jentsch-Ullrich K et al (2005) Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 92:1349–1351

    PubMed  CAS  Google Scholar 

  14. Goldschmidt N, Linetsky E, Shalom E et al (2003) High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 98:1239–1242

    PubMed  Google Scholar 

  15. Komrokji RS, Uppal NP, Khorana AA et al (2006) Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 47:1029–1033

    PubMed  Google Scholar 

  16. Mohren M, Markmann I, Jentsch-Ullrich K et al (2006) Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer 4:200–202

    Google Scholar 

  17. Ziegler S, Sperr WR, Knobl P et al (2005) Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 115:59–64

    PubMed  CAS  Google Scholar 

  18. Hugo JZ, Jeanet DM (2006) Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thrombos J 4:11

    Google Scholar 

  19. Srkalovic G, Cameron MG, Rybicki L et al (2004) Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101:558–566

    PubMed  Google Scholar 

  20. Zangari M, Saghafifar F, Anaissie E et al (2002) Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13:187–192

    PubMed  CAS  Google Scholar 

  21. Chew HK, Wun T, Harvey D et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464

    PubMed  Google Scholar 

  22. Tetsche MS, Norgaard M, Pedersen L et al (2006) Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer 6:189

    PubMed  Google Scholar 

  23. Sorensen HT, Mellemkjaer L, Olsen JH et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850

    PubMed  CAS  Google Scholar 

  24. Alexy T, Pais E, Wenby RB et al (2005) Measurement of whole blood viscosity profiles via an automated viscometer: technical details and clinical relevance. Clin Lab 51:523–529

    PubMed  Google Scholar 

  25. Philippe F, Lacombe C, Bucherer C et al (2001) Whole blood viscosity measurement in acute myocardial infarction: feasibility and significance. J Malad Vascul 26:243–247

    CAS  Google Scholar 

  26. Bell W (1973) Defibrinogenation with Arvin. In: Brinkhouse KM (ed) Thombosis: mechanism and control. FA Schattauer Verlag, Stuttgart pp. 371–375

    Google Scholar 

  27. Resch KL EE (1994) Fibrinogen and viscosity: risk factors for cardiovascular events. Compr Ther 20:170–173

    PubMed  CAS  Google Scholar 

  28. Lowe GD (2005) Fibrin D-dimer and cardiovascular risk. Semin Vasc Med 5:387–398

    PubMed  Google Scholar 

  29. Masuda H, Kurita Y, Fukuta K et al (1998) Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 5:418–422

    PubMed  CAS  Google Scholar 

  30. Wojtukiewicz MZ, Zacharski LR, Memoli VA et al (1990) Fibrinogenfibrin transformation in situ in renal cell carcinoma. Anticancer Res 10:579–582

    PubMed  CAS  Google Scholar 

  31. Koh SC, Khalil R, Lim FK et al (2006) The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 12:3–8

    PubMed  CAS  Google Scholar 

  32. Ogata Y, Hepplmann CJ, Charlesworth MC et al (2006) Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. J Proteome Res 5:3318–3325

    PubMed  CAS  Google Scholar 

  33. McGrath MA, Penny R (1976). Paraproteinemia: blood hyperviscosity and clinical manifestations. J Clin Invest; 58:1155–1162

    PubMed  CAS  Google Scholar 

  34. Foester J (1998) Cryoglobulins and cryoglobulinemia. Lee GR FJ, Lukens J, Paraskevas F, et al (eds) Wintrobe’s Clinical Haematology. Williams & Wilkins, Baltimore pp 2725–2737

    Google Scholar 

  35. Wasserman LR, Balcerzak SP, Berk PD et al (1981) Influence of therapy on causes of death in polycythemia vera. Trans Assoc Am Physicians 94:30–38

    PubMed  CAS  Google Scholar 

  36. Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224–2232

    PubMed  Google Scholar 

  37. Pearson TC, Wetherley-Mein G (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2:1219–1222

    PubMed  CAS  Google Scholar 

  38. Spivak JL (2002) Polycythemia vera: myths, mechanisms, and management. Blood 100:4272–4290

    PubMed  CAS  Google Scholar 

  39. Schafer AI (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107:4214–4222

    PubMed  CAS  Google Scholar 

  40. Berk PD WL, Fruchtman SM, Goldberg JD (1995) Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR BP, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. W.B. Sauders, Philadelphia, PA pp 166–194

    Google Scholar 

  41. Di Nisio M, Barbui T, Di Gennaro L et al (2007) The haematocrit and platelet target in polycythemia vera. Br J Haematol 136:249–259

    PubMed  Google Scholar 

  42. Landolfi R, Ciabattoni G, Patrignani P et al (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 80:1965–1971.

    PubMed  CAS  Google Scholar 

  43. Kwaan HC, Bongu A (1999) The hyperviscosity syndromes. Semin Thromb Hemost 25:199–208

    PubMed  CAS  Google Scholar 

  44. Cukierman T, Gatt ME, Libster D et al (2002) Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma 43:1865–1868.

    PubMed  Google Scholar 

  45. Khorana AA, Francis CW, Culakova E et al (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104:2822–2829

    PubMed  Google Scholar 

  46. Chang VT, Aviv H, Howard LM et al (2003) Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature. Am J Hematol 72:20–26

    PubMed  Google Scholar 

  47. Otten TR, Stein PD, Patel KC et al (2003) Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 123:809–812

    PubMed  Google Scholar 

  48. Mamede RC, Resende e Almeida KO, de Mello-Filho FV (2004) Neck mass due to thrombosis of the jugular vein in patients with cancer. Otolaryngol Head Neck Surg 131:968–972

    PubMed  Google Scholar 

  49. Hiraiwa K, Morozumi K, Miyazaki H et al (2006) Isolated splenic vein thrombosis secondary to splenic metastasis: a case report. World J Gastroenterol 12:6561–6563

    PubMed  Google Scholar 

  50. Inoue H, Yasu T, Kawahito K et al (2006) Successfully treated massive pulmonary thromboembolism and thrombus in the right atrium due to diffuse malignant lymphoma: a case report. J Cardiol 48:159–163

    PubMed  Google Scholar 

  51. Bergqvist D (2006) Venous thromboembolism: a review of risk and prevention in colorectal surgery patients. Dis Colon Rectum 49:1620–1628

    PubMed  Google Scholar 

  52. Mason DP, Quader MA, Blackstone EH et al (2006) Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg 131:711–718

    PubMed  Google Scholar 

  53. Andtbacka RH, Babiera G, Singletary SE et al (2006) Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 243:96–101.

    PubMed  Google Scholar 

  54. Martino MA, Borges E, Williamson E et al (2006) Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstetrics Gynecol 107:666–671.

    Google Scholar 

  55. Smith SF, Simpson JM, Sekhon LH (2004) Prophylaxis for deep venous thrombosis in neurosurgical oncology: review of 2,779 admissions over a 9-year period. Neurosurg Focus 17:E4

    PubMed  Google Scholar 

  56. Agnelli G, Bolis G, Capussotti L et al (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243:89–95

    PubMed  Google Scholar 

  57. Le Treut YP, Hardwigsen J, Ananian P et al (2006) Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg 10:855–862

    PubMed  Google Scholar 

  58. Chen XP, Qiu FZ, Wu ZD et al (2006) Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 13:940–946.

    PubMed  Google Scholar 

  59. Ikai I, Hatano E, Hasegawa S et al (2006) Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein. J Am College Surgeons 202:431–438

    Google Scholar 

  60. Zini L, Haulon S, Leroy X et al (2006) Endoluminal occlusion of the inferior vena cava in renal cell carcinoma with retro-or suprahepatic caval thrombus. BJU international 97:1216–1220

    PubMed  Google Scholar 

  61. Jiang H, Zhang ZG, Chen ZD et al (2006) Renal cell carcinoma with vena caval tumor thrombus extending into the right atrium. Chinese Med J 119:1934–1936

    Google Scholar 

  62. Sakuma M, Fukui S, Nakamura M et al (2006) Cancer and pulmonary embolism: thrombotic embolism, tumor embolism, and tumor invasion into a large vein. Circ J 70:744–749

    PubMed  Google Scholar 

  63. Reyes MA, Ciancio G, Singal R et al (2006) Adrenocortical carcinoma with tumor thrombus in the right hepatic vein. Int J Urol 13:1233–1235.

    PubMed  Google Scholar 

  64. Aryana A, Esterbrooks DJ, Morris PC (2006) Nonbacterial thrombotic endocarditis with recurrent embolic events as manifestation of ovarian neoplasm. J Gen Intern Med 21:C12–C15

    PubMed  Google Scholar 

  65. Buckendahl AC, Martens F, Scholman HJ et al (2006) Acute myocardial infarction caused by coronary tumor thromboembolism: a rare primary manifestation of malignant tumor disease. Human Pathol 37:236–238

    Google Scholar 

  66. Rickles FR, Falanga A (2001) Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102:V21–V24

    Google Scholar 

  67. Brusselmans K, Bono F, Collen D et al (2005) A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem 280:3493–3499

    PubMed  CAS  Google Scholar 

  68. Salgado R, Benoy I, Weytjens R et al (2002) Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer 87:1437–1444

    PubMed  CAS  Google Scholar 

  69. Yan SF, Mackman N, Kisiel W et al (1999) Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 19:2029–2035

    PubMed  CAS  Google Scholar 

  70. Anderson KC (2003) The role of immunomodulatory drugs in multiple myeloma. Semin Hematol [Suppl 4] 40:23–32

    Google Scholar 

  71. Anderson KC (2003) Moving disease biology from the lab to the clinic. Cancer 97[Suppl 3]:796–801

    PubMed  Google Scholar 

  72. Berenson JR, Jagannath S, Barlogie B et al (2005) Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104:2141–2148

    PubMed  CAS  Google Scholar 

  73. Chauhan D, Uchiyama H, Akbarali Y et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104–1112

    PubMed  CAS  Google Scholar 

  74. Urashima M, Ogata A, Chauhan D et al (1996) Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 87:1928–1938

    PubMed  CAS  Google Scholar 

  75. Podar K, Tai YT, Davies FE et al (2001) Vascular endothelial growth factor triggers signalling cascades mediating multiple myeloma cell growth and migration. Blood 98:428–435

    PubMed  CAS  Google Scholar 

  76. Hideshima T, Chauhan D, Schlossman R et al (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519–4527

    PubMed  CAS  Google Scholar 

  77. Fibach E, Treves A, Korenberg A et al (1985) In vitro generation of procoagulant activity by leukemic promyelocytes in response to cytotoxic drugs. Am J Hematol 20:257–265

    PubMed  CAS  Google Scholar 

  78. Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401–410

    PubMed  Google Scholar 

  79. Grignani G, Maiolo A (2000) Cytokines and hemostasis. Haematologica 85:967–972

    PubMed  CAS  Google Scholar 

  80. Leone G, Sica S, Chiusolo P et al (2001) Blood cell diseases and thrombosis. Haematologica 86:1236–1244

    PubMed  CAS  Google Scholar 

  81. De Gaetano G, Cerletti C, Evangelista V (1999) Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis 29:41–49

    PubMed  Google Scholar 

  82. Gale AJ, Gordon SG (2001) Update on tumor cell procoagulant factors. Acta Haematol 106:25–32

    PubMed  CAS  Google Scholar 

  83. Falanga A (2005) Thrombophilia in cancer. Semin Thromb Haemost 31:104–110

    Google Scholar 

  84. Kwaan HC, Parmar S, Wang J (2003) Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Haemost 29:283–290

    CAS  Google Scholar 

  85. Negaard H, Dahm A, Sandset PM et al (2005) Angiogenesis and hemostasis in hematological neoplasias. Curr Drug Targets 6:683–699

    PubMed  CAS  Google Scholar 

  86. Rickles FR, Shoji M, Abe K (2001) The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 73:145–150

    PubMed  CAS  Google Scholar 

  87. Bach RR (2006) Tissue factor encryption. Arterioscler Thromb Vasc Biol 26:456–461

    PubMed  CAS  Google Scholar 

  88. Bach R, Gentry R, Nemerson Y (1986) Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 25:4007–4020

    PubMed  CAS  Google Scholar 

  89. Kamikura Y, Wada H, Nobori T et al (2005) Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res 116:307–312

    PubMed  CAS  Google Scholar 

  90. Sase T, Wada H, Yamaguchi M et al (2005) Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 93:153–159

    PubMed  CAS  Google Scholar 

  91. Kamikura Y, Wada H, Sase T et al (2006) Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy. Thromb Res 117:671–679

    PubMed  CAS  Google Scholar 

  92. Han LY, Landen CN Jr, Kamat AA et al (2006) Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 24:755–761

    PubMed  CAS  Google Scholar 

  93. Uno K, Homma S, Satoh T et al (2007) Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 96:290–295

    PubMed  CAS  Google Scholar 

  94. Altomare DF, Rotelli MT, Pentimone A et al (2007) Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence. Colorectal Dis 9:133–138

    PubMed  CAS  Google Scholar 

  95. Haas SL, Jesnowski R, Steiner M et al (2006) Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 12:4843–4849

    PubMed  CAS  Google Scholar 

  96. Yamashita H, Kitayama J, Ishikawa M et al (2007) Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 95:324–331

    PubMed  CAS  Google Scholar 

  97. Nadir Y, Katz T, Sarig G et al (2005) Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica 90:1549–1556

    PubMed  CAS  Google Scholar 

  98. Falanga A, Gordon SG (1985) Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 24:5558–5567

    PubMed  CAS  Google Scholar 

  99. Kazmierczak M, Lewandowski K, Wojtukiewicz MZ et al (2005) Cancer procoagulant in patients with adenocarcinomas. Blood Coagul Fibrinolysis 16:543–547

    Article  PubMed  Google Scholar 

  100. Falanga A, Consonni R, Marchetti M et al (1998) Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 92:143–151

    PubMed  CAS  Google Scholar 

  101. Olas B, Mielicki WP, Wachowicz B et al (1999) Cancer procoagulant stimulates platelet adhesion. Thromb Res 94:199–203

    PubMed  CAS  Google Scholar 

  102. Kwaan HC (1992) The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11:291–311

    PubMed  CAS  Google Scholar 

  103. _Kwaan HC, Wang J, Svoboda K et al (2000) Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 82:1702–1708

    PubMed  CAS  Google Scholar 

  104. Menell JS, Cesarman GM, Jacovina AT et al (1999) Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340:994–1004

    PubMed  CAS  Google Scholar 

  105. Soff GA, Sanderowitz J, Gately S et al (1995) Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96:2593–2600

    Article  PubMed  CAS  Google Scholar 

  106. Lisman T, de Groot PG, Meijers JC et al (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105:1102–1105

    PubMed  CAS  Google Scholar 

  107. Lyons RM, Keski-Oja J, Moses HL (1988) Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 106:1659–1665

    PubMed  CAS  Google Scholar 

  108. Wilson EL, Jacobs P, Dowdle EB (1983) The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood 61:568–574

    PubMed  CAS  Google Scholar 

  109. Wilson EL, Jacobs P, Dowdle EB (1983) The effects of dexamethasone and tetradecanoyl phorbol acetate on plasminogen activator release by human acute myeloid leukemia cells. Blood 61:561–567

    PubMed  CAS  Google Scholar 

  110. Martin SJ, Reutelingsperger CP, McGahon AJ et al (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1545–1556

    PubMed  CAS  Google Scholar 

  111. Fadok VA, Voelker DR, Campbell PA et al (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148:2207–2216

    PubMed  CAS  Google Scholar 

  112. Flynn PD, Byrne CD, Baglin TP et al (1997) Thrombin generation by apoptotic vascular smooth muscle cells. Blood 89:4378–4384

    PubMed  CAS  Google Scholar 

  113. Casciola-Rosen L, Rosen A, Petri M et al (1996) Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 93:1624–1629

    PubMed  CAS  Google Scholar 

  114. Wang J, Weiss I, Svoboda K, Kwaan HC (2001) Thrombogenic role of cells undergoing apoptosis. Br J Haematol 115:382–391

    PubMed  CAS  Google Scholar 

  115. Barbui T, Finazzi G, Falanga A (1998) The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 91:3093–3102

    PubMed  CAS  Google Scholar 

  116. Tallman MS, Lefebvre P, Baine RM et al (2004) Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2:1341–1350

    PubMed  CAS  Google Scholar 

  117. Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745–749

    PubMed  CAS  Google Scholar 

  118. Antoniou D, Pavlakou G, Stathopoulos GP et al (2006) Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer 53:205–210

    PubMed  Google Scholar 

  119. Blann AD, Gurney D, Wadley M et al (2001) Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis 12:43–50

    PubMed  CAS  Google Scholar 

  120. _Simak J, Gelderman MP (2006) Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 20:1–26

    PubMed  Google Scholar 

  121. Shebuski RJ, Kilgore KS (2002) Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 300:729–735

    PubMed  CAS  Google Scholar 

  122. Horstman LL, Jy W, Jimenez JJ et al (2004) New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 53:210–230

    PubMed  CAS  Google Scholar 

  123. Hron G, Kollars M, Weber H et al (2007) Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97:119–123

    PubMed  CAS  Google Scholar 

  124. _Tesselaar ME, Romijn FP, van der Linden IK et al (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5:520–527

    PubMed  CAS  Google Scholar 

  125. Dixit A, Kannan M, Mahapatra M et al (2006) Roles of protein C, protein S, and antithrombin III in acute leukemia. Am J Hematol 81:171–174

    PubMed  CAS  Google Scholar 

  126. Haim N, Lanir N, Hoffman R et al (2001) Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 110:91–96

    PubMed  CAS  Google Scholar 

  127. Sarig G, Michaeli Y, Lanir N et al (2005) Mechanisms for acquired activated protein C resistance in cancer patients. J Thromb Haemost 3:589–590

    PubMed  CAS  Google Scholar 

  128. Green D, Maliekel K, Sushko E et al (1997) Activated-protein-C resistance in cancer patients. Haemostasis 27:112–118

    PubMed  CAS  Google Scholar 

  129. Nojima J, Kuratsune H, Suehisa E et al (2002) Acquired activated protein C resistance is associated with the coexistence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 118:577–583

    PubMed  CAS  Google Scholar 

  130. Gomez-Puerta JA, Cervera R, Espinosa G et al (2006) Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 35:322–332

    PubMed  CAS  Google Scholar 

  131. Pusterla S, Previtali S, Marziali S et al (2004) Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 5:341–346

    PubMed  CAS  Google Scholar 

  132. Genvresse I, Luftner D, Spath-Schwalbe E et al (2002) Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma. Eur J Haematol 68:84–90

    PubMed  CAS  Google Scholar 

  133. Khan S, Dickerman JD (2006) Hereditary thrombophilia. Thromb J 4:15

    PubMed  Google Scholar 

  134. Simioni P, Tormene D, Spiezia L et al (2006) Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost 32:700–708

    PubMed  CAS  Google Scholar 

  135. Leroyer C, Mercier B, Oger E et al (1998) Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 80:49–51

    PubMed  CAS  Google Scholar 

  136. Abramson N, Costantino JP, Garber JE et al (2006) Effect of Factor V Leiden and prothrombin G20210—>A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 98:904–910

    Article  PubMed  CAS  Google Scholar 

  137. Elice F, Fink L, Tricot G et al (2006) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134:399–405

    PubMed  CAS  Google Scholar 

  138. Di Micco P, Niglio A, De Renzo A et al (2004) Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report. J Transl Med 2:7

    PubMed  Google Scholar 

  139. Agnelli G, Verso M (2006) Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nature Clin Practice 3:214–222

    Google Scholar 

  140. Lokich JJ, Becker B (1983) Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 52:1586–1589

    PubMed  CAS  Google Scholar 

  141. Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665–3675

    PubMed  Google Scholar 

  142. Monreal M, Munoz FJ, Rosa V et al (2006) Upper extremity DVT in oncological patients: analysis of risk factors. Data from the RIETE registry. Exp Oncol 28:245–247

    PubMed  CAS  Google Scholar 

  143. Lee AY, Levine MN, Butler G et al (2006) Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24:1404–1408

    PubMed  Google Scholar 

  144. Cortelezzi A, Moia M, Falanga A et al (2005) Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 129:811–817

    PubMed  Google Scholar 

  145. Webert K, Cook RJ, Sigouin CS et al (2006) The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 91:1530–1537

    PubMed  Google Scholar 

  146. Spectre G, Libster D, Grisariu S et al (2006) Bleeding, obstruction, and perforation in a series of patients with aggressive gastric lymphoma treated with primary chemotherapy. Ann Surg Oncol 13:1372–1378

    PubMed  Google Scholar 

  147. Deshpande A, Storch I, Barkin J (2007) Diagnosis of lymphoma in overt obscure GI bleeding aided by capsule endoscopy. Gastrointest Endosc 65:159–160

    PubMed  Google Scholar 

  148. Koornstra JJ, Schot BW, Dijkstra G (2007) Mantle cell lymphoma involving the appendiceal orifice as an unusual cause of lower gastrointestinal bleeding. Int J Colorectal Dis 22:99–100

    PubMed  Google Scholar 

  149. Okajima K, Sakamoto Y, Uchiba M (2000) Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases. Am J Hematol 65:215–222

    PubMed  CAS  Google Scholar 

  150. Tapiovaara H, Matikainen S, Hurme M et al (1994) Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood 83:1883–1891

    PubMed  CAS  Google Scholar 

  151. Kwaan HC, Wang J, Weiss I (2004) Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J Thromb Haemost 2:306–312

    PubMed  CAS  Google Scholar 

  152. Dally N, Hoffman R, Haddad N et al (2005) Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemiaa single center experience in 34 patients. Thromb Res 116:109–114

    PubMed  CAS  Google Scholar 

  153. Boggio LN, Green D (2001) Acquired hemophilia. Rev Clin Exp Hematol 5:389–404

    PubMed  CAS  Google Scholar 

  154. Collins PW, Hirsch S, Baglin TP et al (2006) Acquired haemophilia A in the UK: a two year national surveillance study by UK Haemophilia Centre Doctors’ Organisation. Blood 109:1870–1877

    PubMed  Google Scholar 

  155. Sallah S, Wan JY (2001) Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 91:1067–1074

    PubMed  CAS  Google Scholar 

  156. Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR (2000) Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 124:730–734

    PubMed  CAS  Google Scholar 

  157. Kucuk O, Kwaan HC, Gunnar W et al (1985) Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 55:702–706

    PubMed  CAS  Google Scholar 

  158. Mitchell LG, Sutor AH, Andrew M (1995) Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost 21:390–401

    PubMed  CAS  Google Scholar 

  159. Mitchell L, Hoogendoorn H, Giles AR et al (1994) Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-Asparaginase-induced antithrombin III deficiency. Blood 83:386–391

    PubMed  CAS  Google Scholar 

  160. Isacson S (1970) Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol 7:212–216

    Article  PubMed  CAS  Google Scholar 

  161. Jorgensen KA, Sorensen P, Freund L (1982) Effect of glucocorticosteroids on some coagulation tests. Acta Haematol 68:39–42

    PubMed  CAS  Google Scholar 

  162. Bennett CL, Schumock GT, Desai AA et al (2002). Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 113:603–606

    PubMed  CAS  Google Scholar 

  163. Singhal S, Mehta J (2002) Thalidomide in cancer. Biomed Pharmacother 56:4–12

    PubMed  CAS  Google Scholar 

  164. Barlogie B, Desikan R, Eddlemon P et al (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492–494

    PubMed  CAS  Google Scholar 

  165. Osman K, Comenzo R, Rajkumar SV (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951–1952

    PubMed  CAS  Google Scholar 

  166. Cavo M, Zamagni E, Cellini C et al (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100:2272–2273

    PubMed  CAS  Google Scholar 

  167. Zangari M, Siegel E, Barlogie B et al (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100:1168–1171

    PubMed  CAS  Google Scholar 

  168. Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050–4053

    PubMed  CAS  Google Scholar 

  169. Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079–2080.

    PubMed  Google Scholar 

  170. Zonder JA, Barlogie B, Durie BG et al (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108:403

    PubMed  CAS  Google Scholar 

  171. Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80:1568–1574

    Article  PubMed  CAS  Google Scholar 

  172. Zangari M, Barlogie B, Anaissie E et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715–721

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, 303 East Chicago Ave., Chicago, IL, 60611, USA

    Hau C. Kwaan & Brian Vicuna

Authors
  1. Hau C. Kwaan
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Brian Vicuna
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Hau C. Kwaan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwaan, H.C., Vicuna, B. Thrombosis and bleeding in cancer patients. Oncol Rev 1, 14–27 (2007). https://doi.org/10.1007/s12156-007-0003-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12156-007-0003-7

Key words